semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Stenoses, Spinal At least 12 weeks of complaints of INC Magnetic resonance imaging showing LSS Age >40 years of age Sufficient knowledge of the Dutch language Signed informed consent  History of lumbar spine surgery >2 lumbar levels operation or needed discectomy Degenerative spondylolisthesis > grade 1 (on a scale of 1 to 4), scoliosis or disc herniation ASA-classification >3 Serious psychopathology Pregnancy Active malignancy Plans to move abroad during study period
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hematologic Neoplasms Patient with malignant haematological pathology 2. Patient who must have an osteo-medullary biopsy for diagnostic purposes 3. Age ≥ 18 years 4. Performance Status < 3 5. Patient with no pelvic bone pain before 6. Patient with normal coagulation balance (TP, Activated Partial Thromboplastin Time, fibrin) and platelet count> 50 G / L 7. Patient affiliated to the social security scheme 8. Patient giving written consent before any specific procedure related to the study  Patient regularly taking antalgic treatments from stage 2 or 3 2. Patient with congenital coagulation disorder or acquired or taking anticoagulant therapy such as: fluindione, acenocoumarol, warfarin, dabigatran, apixaban or rivaroxaban 3. Contraindication to a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen administration: true allergy, severe respiratory failure requiring continuous oxygen therapy, emphysema, pneumothorax, history of air embolism or diving accident, epilepsy or uncontrolled neurological disorder, unsubstituted vitamin deficiency B12 and folic acid, abdominal gas distension 4. Any contraindication to the use of the headset: pacemaker or other implanted medical device 5. Pregnancy or breastfeeding 6. Persons deprived of liberty, under guardianship or under guardianship 7. Dementia, mental impairment or psychiatric condition that may compromise patient informed consent and / or protocol compliance and follow-up of the trial 8. Patient unable to undergo protocol monitoring for psychological, social, family or geographical reasons
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Edema Planned for total knee arthroplasty BMI ≥30 kg/m2, aged 18 or older Speaks, reads and understands Danish Written informed consent  Peripheral Arterial Disease Arterial insufficiency No palpable puls at the arteria dorsalis pedis Severe atherosclerosis Leg ulcers Skin disease Fragile "tissue paper" skin Neuropathy or other cause of sensory impairment Allergy to the stocking material Massive leg edema or pulmonary edema from congestive cardiac failure
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bell's Palsy Facial Nerve Paresis English as primary language Acute unilateral facial palsy without skin lesions which developed within a 72-hour period and is present for 21 days or less Moderate to severe facial palsy [House-Brackmann grade IV or greater]  Another cause of facial nerve paralysis that is not idiopathic Otologic disease including otitis media, temporal bone fracture, a previous history of facial nerve palsy in either side, history of otologic surgery, and suspected Ramsay Hunt syndrome Systemic disease including history of tuberculosis, history of head and neck cancer, other neurological disorders, recent use of ototoxic medications, liver or renal dysfunction, and other illnesses that would contraindicate the use of high-dose steroid therapy Pregnancy
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Rare Diseases Orphan Diseases first contact with the Center for Rare Diseases for unclear diagnosis suspicion of a rare disease but no established diagnosis attending the Center for Rare Diseases as an outpatient written informed consent  age <12 years incomplete medical records including summary letters, imaging studies, blood tests etc pre-diagnosed disease(s) explaining all symptoms
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Coronary Angiography Sedative Premedication elective coronary angiography  planned PCI use of sedative medication at home use of alcohol
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 5.0-8.0,  Pulp Disease, Dental Cooperative patient 2. Healthy 5-8 years old patient with at least one carious primary molar tooth at each side of the patient's mouth. 3. Presence of at least two-thirds of the root length radiographically. 4. Restorable tooth. 5. No signs of hyperemia and hemostasis will be adequately achieved with moistened cotton pellet within 5 minutes after coronal pulp amputation  Teeth showing clinical and radiographic evidence of pulp degeneration such as history of spontaneous or nocturnal pain, tenderness to percussion or palpation, pathologic mobility, swelling or fistulous tract, periodontal ligament (PDL) space widening, internal root resorption, external root resorption, furcal radiolucency/inter- radicular bone destruction and/or periapical bone destruction. 2. Patients eliciting history of known allergy to pollens associated with propolis. 3. Parent or guardian refusal to participate
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Pain Adults over age 18 Have chronic pain (pain on most days or everyday) for the past 3 months or more Able to attend 1 CPSMP workshop a week over 6 weeks Able to attend 3-4 testing sessions for data collection (testing sessions are scheduled before the workshops begin and then six months, one year and, for those assigned to the control group, one and a half years after the start of the study)  Chronic pain caused by current cancer diagnosis or an open wound Lack reliable transportation Having surgery for the painful area in the next year Not community-dwelling (i.e., living in a nursing home, assisted living or personal care home, mental hospital, or correctional facility) Not willing to be randomized to either start CPSMP workshop now or in six months Participation in another self-management program (e.g., Diabetes Self-Management Program) in the past 12 months Unable to speak English
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Oncology Pain, Acute Pain, Chronic The patient is over 18 years of age Irruptive oncological pain The patient has a mobile phone with Android operating system The patient has the physical ability to use the application The patient does not present psychological and / or cognitive alterations or problems with language that make their participation difficult The patient voluntarily wants to participate and signs the informed consent  The patient is under 18 years The patient does not have a mobile phone or has a mobile phone in which Android is not the operating system (the app is currently only available for Android for economic reasons) The patient does not have the physical capacity to use the application The patient does not have the capacity to participate due to psychological and / or cognitive alterations or problems with language The patient does not want to participate
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 60.0-75.0,  Kinesio Taping Knee Osteoarthritis • Female subjects aged 60 years and over, non-obese (BMI between 18.5 and 24.9 kg / m2), with diagnosis of knee OA according to the of the American College of Rheumatology (Altman et al. , 1986), which are: knee pain most of the day during the last weeks and age greater than 60 years (mandatory criteria), and at least two of the following stiffness after rest less than 30 minutes, crackle in the affected knee , joint increase of firm consistency, absence of temperature increase and painful hypersensitivity to palpation Individuals with radiographic signs of degeneration of the knee joint Individuals with any degree of degeneration according to the Kellgren-Lawrence scale Individuals with a pain scale above 3 according to NPRS Stiffness in the knee for at least 6 months prior to screening Stiffness during the beginning of activities Intermittent swelling Never have used KT Individuals with no history of associated joint disease or systemic rheumatic disease and / or history of surgery in the affected lower limb Individuals who are not under physiotherapeutic treatment during the intervention  • Individuals who report pain during the procedure Individuals who do not complete the treatment time or who do not perform the evaluation procedures correctly, making it impossible to collect any of the data investigated Individuals with allergy to bandage or cutaneous injury in the region where KT will be applied Individuals who present hypertensive peak during the evaluations
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Kidney Disease End Stage Kidney Disease Chronic Kidney Disease Mineral and Bone Disorder Renal Osteodystrophy Secondary Hyperparathyroidism Chronic kidney disease stage 3, 4 or 5 Stable dose of vitamin D for 2-months  Dialysis Current use or treatment in the past one year with oral or inhaled glucocorticoids for more than 90 days Current use or treatment in the past one year with sex hormone/SERM therapy for more than 30 days Any use of bisphosphonates Use of anti-osteoporosis therapies (denosumab, teriparatide, calcitonin or anti-sclerostin antibodies) in last 2 years Any solid organ transplant or bone marrow transplant (Not including skin or cornea) Patients on non-aspirin anticoagulants that cannot be reasonably held for biopsy Any cancers within 5-yrs of diagnosis that were metastatic to bone, and that are not in complete remission Any history of leukemia, multiple myeloma, lymphoma, amyloid or paraproteinemias Any congenital or acquired collagen of bone diseases other than osteoporosis or renal osteodystrophy (Including but not limited to: Osteogenesis Imperfecta, X-Linked Hypophosphatemic Rickets, Pagets or Cushings Disease)
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Talus Fracture diagnosis of a closed, isolated, displaced talar neck or body fracture with 2 or more millimetres displacement, subsequently treated by ORIF age between 18 and 85 years informed consent to participate  undisplaced fractures or involvement of both the neck and the body open fractures, talar head and peripheral fractures including posterior process, osteochondral fractures, primary arthrodesis or amputation history of severe neurological deficit previous foot surgery or trauma diagnosis of rheumathological diseases or psoriatic arthritis, foot neuropathy, severe vascular insufficiency and alcohol or drug abuse
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Alveolar Osteitis The are cooperative adult patients able to fulfil the study protocol needing surgical extractions of both lower third molars with similar surgical difficulty according to Pederson scale  The are refuse to participate in the study failure to attend 24, 48, and 72 hours, as well as, 7 days post-surgical appointment visits smokers systemic diseases as diabetes mellitus or being immunosuppressed patients who take local or systemic antibiotics less than 3 months ago, anti-inflammatory or anticoagulant medication in the previous 4 weeks patients who require antibiotic prophylaxis pregnant or breastfeeding women patients with chronic periodontitis in active phase or
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Articular Cartilage Disorder of Knee Given written informed consent on the IRB approved consent form specific to the study, prior to study participation 50 years old Male or Female Suspected chondral damage in the following locations where debridement is indicated Medial femoral condyle Lateral femoral condyle Trochlea Patella < 30% joint space narrowing as seen on x-ray (merchant view, AP and PA Rosenberg) or more chondral lesion(s) as noted on MRI  Previous chondral treatment in the same compartment (prior debridement and lavage performed more than three months prior to baseline are acceptable) Focal chondral defect indicated for concomitant procedures (i.e., microfracture, ACI, MACI, OATs) Concomitant procedures that are not allowed Lateral retinacular release Excision of osteophytes Subchondroplasty Manipulation under anesthesia ACL reconstruction Quad tendon repair Patellar tendon repair